Fuente: WSJ Markets ↗
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
|
Traducción no disponible. Inténtalo de nuevo.
Lo que informa la fuente
Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Leer el informe original en WSJ Markets ↗